Furthermore, the group at greater risk activated inflammation-promoting function, type II IFN response, type I interferon (IFN) response, T_cell_co_inhibition, and APC_co_inhibition, indicating that activation of the above pathway in patients at greater risk can impact cancer patients undergoing immunotherapy, limiting the effectiveness of immune treatment and promoting tumor evasion from immune attacks (Fig. 10F). This evidence concerns the gene IFNA1 and cancer.